SA520411768B1 - تركيبات مصل ثابتة تشتمل، من بين أشياء أخرى، على فيروس مصفّر محور جينيًا موهن حي وعملية لتحضيرها - Google Patents

تركيبات مصل ثابتة تشتمل، من بين أشياء أخرى، على فيروس مصفّر محور جينيًا موهن حي وعملية لتحضيرها

Info

Publication number
SA520411768B1
SA520411768B1 SA520411768A SA520411768A SA520411768B1 SA 520411768 B1 SA520411768 B1 SA 520411768B1 SA 520411768 A SA520411768 A SA 520411768A SA 520411768 A SA520411768 A SA 520411768A SA 520411768 B1 SA520411768 B1 SA 520411768B1
Authority
SA
Saudi Arabia
Prior art keywords
live attenuated
attenuated recombinant
inter alia
preparation
vaccine compositions
Prior art date
Application number
SA520411768A
Other languages
English (en)
Inventor
مهالاساكانت دهيري راجيف
ميهلا راجيف
بابوراف سونار روهيت
دينكار باراسكار سانديب
جاناردان جهوديكار شاشيكانت
كومار فينيت
راجيندرا يوليكار لينا
Original Assignee
سيرم إنستيتيوت اوف انديا بريفت ليمتد
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by سيرم إنستيتيوت اوف انديا بريفت ليمتد filed Critical سيرم إنستيتيوت اوف انديا بريفت ليمتد
Publication of SA520411768B1 publication Critical patent/SA520411768B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

يتعلق الإختراع الحالى بتركيبات مناعية مجفدة مستقرة stable lyophilized immunogenic compositions تشمل من بين أشياء أخرى فيروسات مصفرة (فيروسات فلافى) حية معادة الإتحاد (مؤتلفة) موهّنة live attenuated recombinant dengue viruses ، ويفضل أكثر فيروسات حمى الضنك الحية معادة الإتحاد (مؤتلفة) الموهّنة، كربوهيدرات carbohydrate واحدة على الأقل، وحمض أمينى amino acid واحد على الأقل ويكون قابل بشكل خاص لمعالجات التجفيف بالتجميد السريعة rapid freeze-drying treatments حيث، تحافظ التركيبة على الخصائص المرغوبة للفيروس virus ، بما فى ذلك قابلية بقاء الفيروس virus viability ، مناعته وإستقراره. تكون التركيبة المناعية immunogenic composition المذكورة خالية من المواد الحافظة والبوليمرات والمواد الخافضة للتوتر السطحى surfactants. وطرق لتصنيع التركيبات المناعية المجفدة المستقرة stable lyophilized immunogenic compositions المذكورة. شكل 1.
SA520411768A 2017-10-16 2020-04-14 تركيبات مصل ثابتة تشتمل، من بين أشياء أخرى، على فيروس مصفّر محور جينيًا موهن حي وعملية لتحضيرها SA520411768B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201721036696 2017-10-16

Publications (1)

Publication Number Publication Date
SA520411768B1 true SA520411768B1 (ar) 2023-12-21

Family

ID=66173564

Family Applications (1)

Application Number Title Priority Date Filing Date
SA520411768A SA520411768B1 (ar) 2017-10-16 2020-04-14 تركيبات مصل ثابتة تشتمل، من بين أشياء أخرى، على فيروس مصفّر محور جينيًا موهن حي وعملية لتحضيرها

Country Status (23)

Country Link
US (1) US11660333B2 (ar)
EP (1) EP3697897A4 (ar)
JP (1) JP7261239B2 (ar)
KR (1) KR20200088326A (ar)
CN (1) CN111655844B (ar)
AR (1) AR114138A1 (ar)
AU (1) AU2018352447A1 (ar)
BR (1) BR112020007513A2 (ar)
CA (1) CA3079151A1 (ar)
CO (1) CO2020006037A2 (ar)
CR (1) CR20200212A (ar)
CU (1) CU24701B1 (ar)
EA (1) EA202090967A1 (ar)
GE (1) GEP20237575B (ar)
MX (1) MX2020004085A (ar)
PE (1) PE20210106A1 (ar)
PH (1) PH12020550266A1 (ar)
SA (1) SA520411768B1 (ar)
SG (1) SG11202003408TA (ar)
TW (1) TWI812650B (ar)
UA (1) UA127829C2 (ar)
WO (1) WO2019077622A1 (ar)
ZA (1) ZA202002852B (ar)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3166063A1 (en) 2013-03-15 2014-09-25 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructs in vaccines
JOP20200140A1 (ar) 2017-12-07 2022-10-30 Merck Sharp & Dohme صيغ لتركيبات لقاح فيروس حُمى الضنك
WO2021119221A1 (en) * 2019-12-10 2021-06-17 Repligen Corporation Methods of preparing viral vectors
EP4100689A2 (en) * 2020-02-04 2022-12-14 Regeneron Pharmaceuticals, Inc. Target residual moisture content for lyophilized drug product
GB2600468A (en) * 2020-10-30 2022-05-04 Excivion Ltd Adjuvant composition
WO2023037387A2 (en) * 2021-09-08 2023-03-16 Serum Institute Of India Private Limited Freeze-dried viral combination vaccine compositions and process for preparation thereof
WO2023158989A1 (en) * 2022-02-15 2023-08-24 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
EP4356925A3 (en) * 2022-10-18 2024-05-01 Takeda Vaccines, Inc. Dengue vaccine formulation
WO2024118740A1 (en) * 2022-11-29 2024-06-06 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8444991B2 (en) * 2007-03-22 2013-05-21 The Regents Of The University Of Colorado, A Body Corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
US8785173B2 (en) * 2008-09-24 2014-07-22 Medimmune, Llc Methods for purification of viruses
CN102202688B (zh) 2008-11-07 2017-04-12 印度血清研究所私人有限公司 稳定、干燥的轮状病毒疫苗、其组合物和制备其的方法
TW201233803A (en) * 2010-12-02 2012-08-16 Oncolytics Biotech Inc Lyophilized viral formulations
AU2013208187B2 (en) 2012-01-09 2018-07-12 Sanofi Pasteur Biologics, Llc Purification of flaviviruses
US10004795B2 (en) 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
WO2017056101A1 (en) 2015-09-30 2017-04-06 Panacea Biotec Limited Stable live attenuated recombinant dengue vaccine
US10751408B2 (en) * 2016-02-23 2020-08-25 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens

Also Published As

Publication number Publication date
US20210187092A1 (en) 2021-06-24
EP3697897A4 (en) 2022-02-23
PE20210106A1 (es) 2021-01-19
CU24701B1 (es) 2024-04-08
KR20200088326A (ko) 2020-07-22
UA127829C2 (uk) 2024-01-17
WO2019077622A1 (en) 2019-04-25
MX2020004085A (es) 2020-12-03
SG11202003408TA (en) 2020-05-28
ZA202002852B (en) 2021-03-31
PH12020550266A1 (en) 2021-03-01
GEP20237575B (en) 2023-12-25
CN111655844A (zh) 2020-09-11
JP2020537691A (ja) 2020-12-24
CR20200212A (es) 2020-07-17
CO2020006037A2 (es) 2020-08-10
TWI812650B (zh) 2023-08-21
TW201922272A (zh) 2019-06-16
AU2018352447A1 (en) 2020-06-11
CN111655844B (zh) 2024-05-24
EA202090967A1 (ru) 2020-08-12
CA3079151A1 (en) 2019-04-25
US11660333B2 (en) 2023-05-30
BR112020007513A2 (pt) 2020-10-06
JP7261239B2 (ja) 2023-04-19
AR114138A1 (es) 2020-07-29
EP3697897A1 (en) 2020-08-26
CU20200036A7 (es) 2021-03-11

Similar Documents

Publication Publication Date Title
SA520411768B1 (ar) تركيبات مصل ثابتة تشتمل، من بين أشياء أخرى، على فيروس مصفّر محور جينيًا موهن حي وعملية لتحضيرها
WO2017156511A8 (en) Live attenuated zika virus vaccine
PH12018500127A1 (en) Vaccine compositions
EP4218807A3 (en) Zika virus vaccine
PH12015500773B1 (en) Methods and compositions for live attenuated viruses
WO2019246363A8 (en) Mosaic influenza virus hemagglutinin polypeptides and uses thereof
AR113257A1 (es) Virus chikungunya inmunogénico
BRPI0915696B8 (pt) composição de vacina de rotavírus liofilizada e método de preparar a referida composição
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
WO2021204825A3 (en) INACTIVATED SARS-CoV-2 VIRUS VACCINE
MX2023012530A (es) Composición y metodos de vacuna adyuvada.
WO2013104995A3 (en) Compositions and methods for treating viral infections
ECSP18026090A (es) Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue
PH12017500450A1 (en) Flavivirus virus like particle
MX2018011839A (es) Constructos de alfavirus vivo atenuado y metodos y usos de los mismos.
MY187896A (en) Dengue virus vaccine compositions and methods of use thereof
NZ631012A (en) Compositions and methods for live, attenuated alphavirus formulations
PH12018500675A1 (en) Stable live attenuated recombinant dengue vaccine
MX2017012389A (es) Vacuna del virus de la parotiditis recombinante jeryl lynn2.
WO2023235660A3 (en) Flavivirus immunogens and vaccine compositions and methods of using the same
WO2023147337A3 (en) Large-scale flaviviral vaccine production and manufacture
BR112016029201B8 (pt) Quimera de ácido nucleico, composição imunogênica, uso de um ou mais vírus inativados compreendendo a quimera de ácido nucleico e método para inativar um vírus
WO2023037387A3 (en) Freeze-dried viral combination vaccine compositions and process for preparation thereof
PH12019550018A1 (en) Porcine reproductive and respiratory syndrome virus cdna clone and uses thereof
EA202090236A1 (ru) Иммуногенные композиции senecavirus a и способы с ними